The   Shkreli —  who is obviously good at numbers, even as he is bad at p. r. —   burst into prominence last September, when he leveraged his perch at a hedge fund and took over Turing Pharmaceuticals he immediately raised the price of one of its drugs by more than 5000 percent. 